Pharming Group Yönetim

Yönetim kriter kontrolleri 2/4

Pharming Group CEO'su Fabrice Chouraqui, Mar2025 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı $ 1.84M olup, şirket hissesi ve opsiyonları dahil olmak üzere 37.3% maaş ve 62.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.94% ine doğrudan sahiptir ve bu hisseler € 7.74M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 5.1 yıldır.

Anahtar bilgiler

Fabrice Chouraqui

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi	37.31%
CEO görev süresi	1.3yrs
CEO sahipliği	0.9%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	5.1yrs

Son yönetim güncellemeleri

Recent updates

Anlatı Güncellemesi • Jun 26

PHARM: Expanded Rare Disease Approvals Will Drive Future Upside Potential

Analysts have raised their price target on Pharming Group to €2.36 from €2.11, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E following the latest research coverage. Analyst Commentary Recent research on Pharming Group highlights a mix of optimism around its growth potential and caution around execution and valuation, giving you a more rounded context for the updated €2.36 price target.

Analiz Makalesi • Sep 08

Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Pharming Group N.V. ( AMS:PHARM ) shareholders have had their patience rewarded with a 26% share price jump in the last...

Analiz Makalesi • May 10

There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise

Pharming Group N.V. ( AMS:PHARM ) shares have had a really impressive month, gaining 29% after a shaky period...

Analiz Makalesi • Dec 21

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

The Pharming Group N.V. ( AMS:PHARM ) share price has done very well over the last month, posting an excellent gain of...

Analiz Makalesi • Feb 14

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

With a price-to-sales (or "P/S") ratio of 3.4x Pharming Group N.V. ( AMS:PHARM ) may be sending very bullish signals at...

Analiz Makalesi • Nov 11

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analiz Makalesi • Aug 23

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Pharming Group is €2.29 based on 2 Stage Free Cash Flow to Equity Current...

Analiz Makalesi • Jun 20

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Analiz Makalesi • Mar 16

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analiz Makalesi • Feb 17

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

In this article we are going to estimate the intrinsic value of Pharming Group N.V. ( AMS:PHARM ) by estimating the...

CEO Tazminat Analizi

Fabrice Chouraqui'un ücretlendirmesi Pharming Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	US$12m
Dec 31 2025	US$2m	US$688k	US$3m

Tazminat ve Piyasa: Fabrice 'nin toplam tazminatı ($USD 1.84M ), Dutch pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.36M ).

Tazminat ve Kazançlar: Fabrice şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Fabrice Chouraqui

1.3yrs

Görev süresi

US$1,844,000

Tazminat

Mr. Fabrice Chouraqui, Ph D., PharmD, M.B.A., serves as the Chief Executive Officer and Executive Director of Pharming Group N.V. since March 4, 2025. He served as the Chief Executive Officer at Cellarity,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fabrice Chouraqui	CEO & Executive Director	1.3yrs	US$1.84m	0.94% € 7.7m
Kenneth Lynard	Chief Financial Officer	less than a year	Veri yok	Veri yok
Mireille Sanders	Chief Operations Officer	6.8yrs	Veri yok	0.17% € 1.4m
Michael Levitan	VP of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Ruud Van Outersterp	Chief Legal & Compliance Officer and Company Secretary	5.1yrs	Veri yok	0.11% € 915.0k
Ines Bernal	Chief People Officer	1.5yrs	Veri yok	0.018% € 147.2k
Anurag Relan	Chief Medical Officer	5yrs	Veri yok	0.14% € 1.1m
Alexander Breidenbach	Chief Business Officer	2.8yrs	Veri yok	0.059% € 486.8k
Leverne Marsh	Chief Commercial Officer	less than a year	Veri yok	Veri yok
Magnus Hansson	Medical Director	no data	Veri yok	Veri yok
Bruno M. Giannetti	Consultant	5yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: PHARM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fabrice Chouraqui	CEO & Executive Director	1.3yrs	US$1.84m	0.94% € 7.7m
Leonard Kruimer	Independent Non-Executive Director	5.1yrs	US$109.00k	0.027% € 222.9k
Mark Pykett	Independent Non-Executive Vice Chairman	5.5yrs	US$100.00k	0.031% € 251.9k
Barbara Yanni	Independent Non-Executive Director	5.5yrs	US$114.00k	0.031% € 251.9k
Richard Peters	Non-Executive Chairman of Board	2.8yrs	US$167.00k	0.022% € 182.1k
Elaine Sullivan	Non Executive Director	1yr	US$73.00k	0.0085% € 69.7k
Jabine T. M. van Meijs	Independent Non-Executive Director	5.1yrs	US$114.00k	0.027% € 222.9k

5.1yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PHARM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/28 05:12
Gün Sonu Hisse Fiyatı	2026/06/26 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Pharming Group N.V. 12 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Whitney Ijem	Canaccord Genuity
John Savin	Edison Investment Research
Simon Scholes	First Berlin Equity Research GmbH

Pharming Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pharming Group N.V., Annual General Meeting, May 28, 2026

Pharming Group N.V. Appoints Kenneth Lynard as Chief Financial Officer, Effective October 1, 2025

Pharming Group N.V. Approves Board Changes

Mr. Jeroen Wakkerman to Leave as Chief Financial Officer of Pharming Group N.V. on May 31, 2025

Pharming Group N.V., Annual General Meeting, Jun 11, 2025

Pharming Group N.V. Announces CEO Changes

Recent updates

PHARM: Expanded Rare Disease Approvals Will Drive Future Upside Potential

Pharming Group N.V. Announces U.S. FDA Acceptance of sNDA Resubmission for Joenja (Leniolisib) to Treat Children Aged 4 to 11 Years with APDS

Investor sentiment deteriorates as stock falls 18%

First quarter 2026 earnings released: US$0.007 loss per share (vs US$0.022 loss in 1Q 2025)

Pharming Group N.V. Receives Positive CHMP Opinion for Joenja® (Leniolisib) for the Treatment of APDS in Adult and Pediatric Patients 12 Years and Older

Pharming Group N.V. Announces Approval of Joenja for Treatment of APDS in Japan

Pharming Group N.V., Annual General Meeting, May 28, 2026

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Pharming Group N.V. to Report Q1, 2026 Results on May 07, 2026

Now 20% undervalued after recent price drop

Pharming Group N.V. Provides Earnings Guidance for the Financial Year 2026

Pharming Group Receives Complete Response Letter from U.S. FDA for sNDA for Joenja (leniolisib) in Children Aged 4 to 11 Years with APDS

Consensus forecasts updated

Price target increased by 7.4% to €2.19

Pharming Group N.V. to Report Q4, 2025 Results on Mar 12, 2026

Pharming Group N.V. Revises Revenue Guidance for Full Year 2025

Pharming Group N.V. Announces Presentations at 2025 ACAAI Annual Scientific Meeting

Pharming Group N.V. Announces 20% Net Reduction in Non-Commercial and Non-Medical Headcount, Primarily at its Netherlands Headquarters

Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Pharming Group N.V. Appoints Kenneth Lynard as Chief Financial Officer, Effective October 1, 2025

Price target increased by 7.2% to €2.04

Price target increased by 13% to €2.01

Second quarter 2025 earnings released: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)

New major risk - Share price stability

Pharming Group N.V. Revises Revenue Guidance for Full Year 2025

Pharming Group to Host Webcast on Findings of A New Study Published in Cell Advancing Functional Classification of Variants of Uncertain Significance (Vus) to Improve APDS Diagnosis

Pharming Group N.V. Approves Board Changes

New major risk - Share price stability

There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise

First quarter 2025 earnings released: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)

Mr. Jeroen Wakkerman to Leave as Chief Financial Officer of Pharming Group N.V. on May 31, 2025

Pharming Group N.V. Receives Positive Recommendation from NICE for Joenja (Leniolisib) as a Treatment for APDS

Consensus EPS estimates upgraded to US$0.015 loss

Price target increased by 14% to €1.94

Pharming Group N.V. Announces First Patient Dosed in Phase II Clinical Trial of Leniolisib for Common Variable Immunodeficiency (CVID) with Immune Dysregulation

Pharming Group N.V., Annual General Meeting, Jun 11, 2025

Full year 2024 earnings: EPS exceeds analyst expectations

Pharming Group N.V. to Report Q2, 2025 Results on Jul 31, 2025

Pharming Group N.V. Announces CEO Changes

Pharming Group N.V. Announces Board Changes

Pharming Group N.V. to Report Q4, 2024 Results on Mar 13, 2025

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

Price target increased by 8.1% to €1.84

Pharming Group N.V. Announces Positive Topline Data in Pediatric Clinical Trial of Leniolisib

New major risk - Share price stability

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director